Evidence map›Paper›PMID 39717696›Full record

ArticleBeilstein journal of nanotechnology2024

Biomimetic nanocarriers: integrating natural functions for advanced therapeutic applications.

Hugo Felix Perini, Beatriz Sodré Matos, Carlo José Freire de Oliveira, Marcos Vinicius da Silva

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Beilstein journal of nanotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Hugo Felix Perini *Department of Immunology, Microbiology and Parasitology. Biological and Natural Sciences Institute. Federal University of Triângulo Mineiro. Uberaba, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0003-1988-7273
Beatriz Sodré Matos *Department of Immunology, Microbiology and Parasitology. Biological and Natural Sciences Institute. Federal University of Triângulo Mineiro. Uberaba, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0002-0342-1017
Carlo José Freire de OliveiraDepartment of Immunology, Microbiology and Parasitology. Biological and Natural Sciences Institute. Federal University of Triângulo Mineiro. Uberaba, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0003-2211-7333
Marcos Vinicius da SilvaDepartment of Immunology, Microbiology and Parasitology. Biological and Natural Sciences Institute. Federal University of Triângulo Mineiro. Uberaba, Minas Gerais, Brazil.ORCID https://orcid.org/0000-0002-2966-7621

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biomimetic nanocarriers, engineered to mimic the characteristics of native cells, offer a revolutionary approach in the treatment of various complex human diseases. This strategy enhances drug delivery by leveraging the innate properties of cellular components, thereby improving biocompatibility and targeting specificity. Biomimetic nanocarriers demonstrate significant advancements in drug delivery systems against cancer therapy, Alzheimer's disease, autoimmune diseases, and viral infections such as COVID-19. Here, we address the therapeutic applications of biomimetic nanocarriers and their promising strategy for personalized medicine.

Indexed as

cancerdrug deliveryhuman healthmimeticsnanotechnology

Identifiers

PMID39717696
PMCPMC11665443

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.